Karyopharm Secures Critical $30M Private Placement, Reports Mixed Phase 3 Myelofibrosis Data, Withdraws DLBCL Approval

summarizeSummary

Karyopharm secured a $30 million private placement, crucial for addressing its going concern warning, and reported mixed Phase 3 myelofibrosis trial results with a promising overall survival signal, while also withdrawing accelerated approval for its DLBCL indication.

check_boxKey Events

• Secured $30 Million Private Placement

  Karyopharm entered into a private placement with RA Capital Management, securing $30 million in gross proceeds by issuing 1,030,354 shares of common stock at $6.785 per share and 3,391,164 pre-funded warrants at $6.7849 per pre-funded warrant, along with 4,421,518 common stock warrants with an exercise price of $10.00 per share. This capital raise is critical for the company, which previously issued a going concern warning.

• Mixed Phase 3 SENTRY Trial Results in Myelofibrosis

  The Phase 3 SENTRY trial for selinexor in myelofibrosis met its first co-primary endpoint (spleen volume reduction of 35% or more) but did not meet the second co-primary endpoint (absolute total symptom score). A promising overall survival signal was observed (HR 0.43, nominal one-sided p=0.0222), and the company plans to discuss the data with the FDA for a potential sNDA filing.

• Withdrawal of DLBCL Accelerated Approval

  The company agreed to voluntarily withdraw the accelerated approval for its Diffuse Large B-Cell Lymphoma (DLBCL) indication of XPOVIO following an FDA request due to the inability to complete a confirmatory trial. Karyopharm stated this indication generates immaterial revenue.

• ATM Program Activity

  In March 2026, Karyopharm sold 1,100,844 shares through its At-The-Market (ATM) program, generating approximately $9.6 million in net proceeds, adding to its liquidity but also contributing to dilution.

auto_awesomeAnalysis

This filing is critical for Karyopharm Therapeutics, which previously issued a going concern warning. The company secured $30 million in gross proceeds from a private placement, with potential for an additional $44 million from warrant exercises. This capital infusion, though highly dilutive and priced at a discount for initial shares, is essential for the company's survival and satisfies a capital raise condition for its credit and forbearance agreements to become effective. Concurrently, the Phase 3 SENTRY trial for selinexor in myelofibrosis showed mixed results, meeting one co-primary endpoint (spleen volume reduction) but missing another (symptom improvement), while demonstrating a promising overall survival signal. The company plans to discuss these results with the FDA for a potential sNDA filing. Additionally, Karyopharm agreed to withdraw the accelerated approval for its DLBCL indication of XPOVIO, citing immaterial revenue from this indication. The company also raised $9.6 million through its ATM program in March. The combination of a significant, albeit dilutive, capital raise and mixed but potentially viable clinical data for a key asset provides a path forward for the company.